Aehr Test Systems
AEHR
$96.73
+6.08%
Aehr Test Systems designs, manufactures, and sells advanced test and burn-in equipment for logic, optical, and memory integrated circuits, operating within the semiconductor capital equipment industry. The company has established a distinct competitive identity as a specialized, high-reliability solutions provider, particularly for the demanding Automotive and Mobility IC markets. The current investor narrative is intensely focused on the company's strategic role in the AI infrastructure build-out, with recent news highlighting massive new bookings and a surge in its stock price driven by a major AI chip testing order, signaling strong validation of its technology and future demand.…
AEHR
Aehr Test Systems
$96.73
Related headlines
Investment Opinion: Should I buy AEHR Today?
Rating: Hold. The core thesis is that while the AI-driven booking catalyst is powerful and transformative, the stock's parabolic move has far outpaced current fundamentals, embedding extreme execution risk and leaving minimal margin of safety for new capital.
Supporting this view are several data points: 1) The stock trades at a forward PS of ~13.2x, a premium multiple demanding flawless execution; 2) Recent quarterly revenue contracted -26.53% YoY with gross margin at 25.75%, showing severe near-term pressure; 3) The company is burning cash (TTM FCF -$11.91M) despite a strong balance sheet (Current Ratio 5.68); 4) The technical picture shows extreme overextension after a +1013% annual gain, increasing near-term volatility risk.
The two biggest risks are a delay in revenue conversion from the $37.2M bookings and a failure to restore profitability, either of which could trigger a violent de-rating. This Hold rating would upgrade to Buy on a significant pullback (e.g., towards $60-70) that offers a better risk/reward entry, or upon confirmation of sequential revenue acceleration and margin expansion in the next 1-2 quarters. Conversely, it would downgrade to Sell if quarterly cash burn accelerates or if bookings fail to materialize into revenue by the next earnings report. The stock is currently overvalued relative to its present financials but may be fairly valuing its future potential, leaving it in a high-risk, transitional state.
Sign up to view all
AEHR 12-Month Price Forecast
The assessment is neutral based on the extreme clash between a transformative forward-looking catalyst and deeply challenged present fundamentals. The $37.2M booking is a game-changer, but the stock's +1013% run has left no room for error. Confidence is medium because the outcome is binary and dependent on flawless execution in the next two quarters. The stance would upgrade to bullish on confirmation of revenue acceleration to >$40M in a single quarter and margin expansion above 35%. It would downgrade to bearish if the next quarterly report shows revenue stagnation <$15M and increased cash burn.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aehr Test Systems's 12-month outlook, with a consensus price target around $125.75 and implied upside of +30.0% versus the current price.
Average Target
$125.75
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$77 - $126
Analyst target range
Analyst coverage for Aehr Test Systems appears limited, with data indicating only one analyst providing estimates for revenue and EPS. This suggests the stock has minimal institutional analyst coverage, which is typical for small to mid-cap companies and can lead to higher volatility and less efficient price discovery. The available data shows an estimated EPS average of $1.14 and revenue average of $196.1 million, but no consensus price target or Buy/Hold/Sell distribution is provided. The recent pattern of institutional ratings shows mixed signals, with William Blair upgrading from 'Market Perform' to 'Outperform' on March 2, 2026, while Craig-Hallum downgraded from 'Buy' to 'Hold' back in March 2024. The lack of a broad consensus target and the wide dispersion in historical analyst actions underscore the high uncertainty and evolving narrative around the company's fundamentals and growth trajectory.
Bulls vs Bears: AEHR Investment Factors
The bull case, driven by a transformative $37.2M AI order and explosive technical momentum, currently holds stronger evidence due to the concrete, forward-looking catalyst that directly addresses near-term financial weakness. However, the bear case presents severe and immediate risks from deteriorating fundamentals, cash burn, and an overextended stock price. The single most important tension in the investment debate is the timing and magnitude of the revenue inflection from new bookings versus the company's ability to fund operations and return to profitability before investor patience wears thin. The stock's fate hinges on converting the massive booking backlog into recognized revenue and restored margins in the coming quarters.
Bullish
- Massive AI Order & Bookings Surge: Recent news confirms a $37.2 million new booking, driven by a major AI chip testing order, which validates Aehr's technology and signals strong future demand. This single booking is nearly 4x the latest quarterly revenue of $9.88 million, providing a clear catalyst for a revenue inflection.
- Extreme Technical Momentum: The stock has delivered staggering returns of +1013.28% over the past year and +135.03% in the last month, decisively breaking out to new highs. This parabolic move, with a beta of 2.289, indicates powerful speculative and fundamental momentum that can sustain further upside if execution continues.
- Strong Balance Sheet for Growth: Aehr maintains a robust financial position with a current ratio of 5.68 and a minimal debt-to-equity ratio of 0.088. This provides significant flexibility to fund operations and capitalize on the AI-driven demand cycle without the immediate pressure of raising dilutive capital.
- High-Growth Forward Valuation: The market is pricing in explosive growth, with a forward Price-to-Sales ratio of approximately 13.2x based on analyst revenue estimates of $196.1 million. This premium multiple reflects strong conviction in the company's ability to scale rapidly from its current $9.88M quarterly revenue run-rate.
Bearish
- Severe Near-Term Financial Deterioration: Recent quarterly results show a -26.53% YoY revenue decline and a gross margin compression to 25.75% from a trailing 40.59%. The company is unprofitable with a net income of -$3.23M and is burning cash, with TTM free cash flow at -$11.91M.
- Parabolic Price Risk & Overextension: Trading at 91% of its 52-week range ($8.02 to $102.48) after a +1013% annual gain, the stock is extremely extended. The extreme volatility (beta 2.289) and recent parabolic ascent create a high risk of a sharp, volatile pullback to consolidate gains, as seen with a recent -42.31% max drawdown.
- Cash Burn & Profitability Concerns: The company is not generating cash from operations, with the latest quarterly operating cash flow at -$1.39M. Despite a strong balance sheet, sustained cash burn at this rate, coupled with negative operating and net margins, raises execution risks if the anticipated revenue ramp is delayed.
- Limited Analyst Coverage & High Uncertainty: Only one analyst provides estimates, indicating minimal institutional coverage which can lead to inefficient price discovery and higher volatility. Mixed recent rating actions (an upgrade to Outperform and an older downgrade to Hold) underscore the high uncertainty surrounding the company's trajectory.
AEHR Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +1013.28%. As of the latest close at $93.07, the price is trading at approximately 91% of its 52-week range ($8.02 to $102.48), positioning it near its all-time highs, which reflects extreme momentum but also raises concerns about potential overextension. Recent momentum is explosive and accelerating, with a 1-month gain of +135.03% and a 3-month gain of +262.99%, far outpacing the broader market's performance (SPY up +9.98% and +4.14% over the same periods). This short-term parabolic move confirms and amplifies the longer-term bullish trend, though the extreme velocity suggests a high likelihood of volatile pullbacks. Key technical support is anchored at the 52-week low of $8.02, while immediate resistance is the 52-week high of $102.48; a breakout above this level would signal a continuation of the speculative frenzy, while a breakdown below the recent consolidation low around $70 would suggest a significant momentum shift. The stock's beta of 2.289 indicates it is approximately 129% more volatile than the SPY, a critical factor for risk management given the stock's recent parabolic ascent.
Beta
3.27
3.27x market volatility
Max Drawdown
-42.3%
Largest decline past year
52-Week Range
$8-$102
Price range past year
Annual Return
+1081.1%
Cumulative gain past year
| Period | AEHR Return | S&P 500 |
|---|---|---|
| 1m | +85.4% | +11.4% |
| 3m | +320.6% | +8.3% |
| 6m | +295.1% | +9.4% |
| 1y | +1081.1% | +31.3% |
| ytd | +336.5% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AEHR Fundamental Analysis
Revenue growth has been volatile but recently showed a sharp sequential decline; the most recent quarterly revenue was $9.88 million, representing a -26.53% year-over-year contraction. However, this headline figure masks the underlying catalyst, as recent news points to a massive $37.2 million in new bookings, which should drive future revenue acceleration. The company is currently unprofitable, with a net income of -$3.23 million and a gross margin of 25.75% for the latest quarter, which is a significant compression from the 40.59% trailing gross margin reported in the valuation data. This margin pressure, alongside negative operating and net margins, indicates the company is investing heavily amid a challenging near-term revenue environment. The balance sheet remains robust with a strong current ratio of 5.68 and a minimal debt-to-equity ratio of 0.088, providing financial flexibility. However, cash flow generation is a concern, with trailing twelve-month free cash flow deeply negative at -$11.91 million and the latest quarterly operating cash flow at -$1.39 million, indicating the company is burning cash to fund operations and growth, reliant on its balance sheet strength.
Quarterly Revenue
$9884000.0B
2025-11
Revenue YoY Growth
-0.26%
YoY Comparison
Gross Margin
+0.25%
Latest Quarter
Free Cash Flow
$-11907000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AEHR Overvalued?
Given the negative net income and EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 4.79, while the forward-looking valuation is implied by the market cap of $2.59 billion against analyst revenue estimates averaging $196.1 million, resulting in a forward PS of approximately 13.2x, indicating the market is pricing in significant future growth. Compared to sector peers, direct industry averages are not provided in the data, but the current trailing PS of 4.79 appears modest for a high-growth semiconductor equipment story, though the implied forward multiple suggests a premium expectation. Historically, the stock's own PS ratio has fluctuated wildly, from a low near 7.77 in May 2021 to a high of 69.83 in November 2025. The current trailing PS of 4.79 is near the lower end of this historical spectrum, which is counterintuitive given the recent price surge; this discrepancy is likely due to a lag in reported financials (revenue of $9.88M) versus the market's forward-looking valuation based on new bookings, placing the stock in a transitional phase between past results and anticipated future performance.
PE
-72.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -111x~168x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-296.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. Aehr is currently burning cash at a rate of -$11.91M TTM free cash flow, with the latest quarterly operating cash flow at -$1.39M, funded by its balance sheet. Revenue declined -26.53% YoY last quarter to $9.88M, and gross margins compressed sharply to 25.75% from a trailing 40.59%, indicating significant operational pressure and investment spend ahead of revenue recognition. The company's valuation (forward PS ~13.2x) is entirely dependent on a rapid and successful execution of its $37.2M+ booking backlog to reverse these trends.
Market & Competitive Risks are elevated due to the stock's extreme valuation and volatility. Trading at a forward PS of ~13.2x implies a massive growth premium that is vulnerable to compression if execution falters or sector sentiment shifts. The stock's beta of 2.289 means it is 129% more volatile than the market, amplifying downside risk during broad market pullbacks. Recent news highlights its role in the AI infrastructure build-out, which, while a catalyst, also ties its fortunes to a potentially cyclical and competitive capex cycle where larger players could emerge.
Worst-Case Scenario involves a failure to convert bookings into timely revenue, coupled with continued margin pressure and cash burn. This could trigger a loss of investor confidence, leading to a rapid de-rating from its premium multiple. A realistic downside could see the stock re-test its 52-week low of $8.02, representing a potential loss of approximately -91% from the current price of $93.07. A more probable severe adverse scenario might involve a pullback to the $30-$40 range (a -58% to -68% decline), aligning with pre-breakout levels and reflecting a valuation reset on delayed growth.
FAQ
The key risks are: 1) Execution Risk: Failure to convert the $37.2M booking backlog into recognized revenue in a timely manner, given the recent -26.53% YoY revenue decline. 2) Financial Risk: Continued cash burn (TTM FCF -$11.91M) and margin pressure (Q2 gross margin 25.75%), which could strain the balance sheet if prolonged. 3) Valuation & Volatility Risk: The stock's parabolic +1013% gain and high beta (2.289) make it prone to violent downdrafts; a max drawdown of -42.31% has already occurred recently. 4) Coverage & Liquidity Risk: Minimal analyst coverage (only one providing estimates) can lead to exaggerated price moves on news and lower liquidity.
The 12-month forecast is bifurcated with high volatility. The base case (50% probability) sees the stock consolidating between $80 and $110 as it digests gains and shows gradual progress on booking conversion. The bull case (30% probability), driven by faster-than-expected revenue growth and new orders, could propel shares to $120-$150. The bear case (20% probability), triggered by execution delays, could see a sharp de-rating to $30-$50. The most likely scenario is the base case, which assumes the company executes adequately but not spectacularly, matching the high expectations already embedded in the stock price after its massive run.
AEHR is overvalued based on its current financials but may be fairly valuing its future potential, creating a paradox. On trailing metrics, with a PS of 4.79 and negative earnings, it looks modest, but this is based on depressed quarterly revenue of $9.88M. The forward-looking valuation, using analyst revenue estimates of $196.1M, implies a forward PS of ~13.2x, which is a premium multiple. This valuation implies the market expects near-perfect execution and 20x revenue growth from the current run-rate. Compared to its own historical PS range (7.77 to 69.83), it is on the lower end, but this reflects a transitional phase between poor past results and anticipated future boom.
AEHR is a high-risk, high-potential stock that is not a good buy for most conservative or income-oriented investors. For aggressive growth investors comfortable with extreme volatility (beta 2.289), it represents a thematic bet on AI infrastructure. The recent $37.2M booking provides a tangible catalyst, but the stock's +1013% annual gain and premium forward PS of ~13.2x leave little margin for error. It could be a good buy on a significant pullback that offers a better risk/reward entry, but at current levels near $93, the risk of a sharp correction outweighs the near-term reward.
AEHR is unsuitable for short-term trading due to its extreme volatility (beta 2.289) and the binary nature of its near-term catalysts; the risk of a swift 20-30% loss is high. It is also a challenging long-term hold until it demonstrates sustainable profitability and cash flow generation. The most appropriate horizon is a medium-term, event-driven holding period of 6-18 months, allowing time for the booking conversion story to play out. Investors should be prepared for a rollercoaster ride and have a clear exit strategy based on either the achievement of revenue targets or the breach of downside support levels.